MPLT - MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.

Sector
Healthcare
Industry
Biotechnology
Market Cap
$23.3M
Beta
3.19
52-Week Range
12.24-33.28
CEO
Christopher A. Kroeger
Employees
109
IPO Date
Oct 24, 2025
Exchange
NASDAQ

MPLT Options Snapshot

Options pricing data for MPLT is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The MPLT overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.

Frequently asked MPLT overview questions

What is MPLT?
MPLT is the ticker symbol for MapLight Therapeutics, Inc., a listed security. MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. Listed on NASDAQ. MPLT is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
What are MPLT's key statistics?
MapLight Therapeutics, Inc. (MPLT) carries a market capitalization of $23.3M, beta of 3.19 relative to the broader market, 52-week range of 12.24-33.28. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
What sector or industry does MPLT belong to?
MapLight Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare MPLT's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the MPLT data on this page?
Options snapshots refresh after each trading session; if no snapshot is currently posted for MPLT, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).